Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
A phase 1/2 trial of CD19-targeted chimeric antigen receptor T-cell in diffuse large B-cell lymphoma and follicular lymphoma, run by Pell Bio-Med Technology Co., Ltd., now recruiting.
Overview
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma is a phase 1/2 interventional study registered as NCT05326243 by Pell Bio-Med Technology Co., Ltd., with 49 participants planned, started 2022-05-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: CD19-targeted chimeric antigen receptor T-cell.
Similar pages
not linked directly; found by shared links- TrialDose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
- TreatmentTC011
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
- TreatmentCRC01
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Shares Diffuse large B-cell lymphoma and the tag pipeline.
- TrialA Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Shares Diffuse large B-cell lymphoma and the tag pipeline.
- TrialA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Shares Diffuse large B-cell lymphoma and the tag pipeline.
- TrialMIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Shares Follicular lymphoma and the tag pipeline.